VRXA (Veraxa Biotech Holding AG) Net Margin %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VRXA Veraxa Biotech Holding AG VRXA
6 GF Score
Price $1.77
! 2 Warning Signs
View Full Analysis

What is Veraxa Biotech Holding AG Net Margin %?

Veraxa Biotech Holding AG VRXA -10.66% 6 Net Margin % is 0.00% as of Dec. 2025. GuruFocus rates VRXA with a GF Score™ of 6/100. The stock has 2 warning signs investors should review. Among 943 Biotechnology companies, Veraxa Biotech Holding AG ranks worse than 98.83% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Veraxa Biotech Holding AG's Net Income for the six months ended in Dec. 2025 was $-37.64 Mil. Veraxa Biotech Holding AG's Revenue for the six months ended in Dec. 2025 was $0.00 Mil. Therefore, Veraxa Biotech Holding AG's net margin for the quarter that ended in Dec. 2025 was 0.00%.

The historical rank and industry rank for Veraxa Biotech Holding AG's Net Margin % or its related term are showing as below:

VRXA' s Net Margin % Range Over the Past 10 Years
Min: -288244.83   Med: -288244.83   Max: -275570
Current: -275570

VRXA's Net Margin % is ranked worse than
98.83% of 943 companies
in the Biotechnology industry
Industry Median: -89.56 vs VRXA: -275570.00

Veraxa Biotech Holding AG  (NAS:VRXA) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Veraxa Biotech Holding AG Net Margin % Related Terms

Veraxa Biotech Holding AG Net Margin % Historical Data

* Premium members only.

The historical data trend for Veraxa Biotech Holding AG's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veraxa Biotech Holding AG Net Margin % Chart

Veraxa Biotech Holding AG Annual Data
Trend Dec23 Dec24 Dec25
Net Margin %
0.00 0.00 -288,244.83

Veraxa Biotech Holding AG Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Net Margin % 0.00 0.00 0.00 -150,103.33 0.00

VRXA vs TTRX, IRD, IFRX: Net Margin % Comparison

For the Biotechnology subindustry, Veraxa Biotech Holding AG's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Veraxa Biotech Holding AG Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Veraxa Biotech Holding AG's Net Margin % distribution charts can be found below:

* The bar in red indicates where Veraxa Biotech Holding AG's Net Margin % falls into.


VRXA
6GF Score
Veraxa Biotech Holding AG VRXA
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veraxa Biotech Holding AG Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Veraxa Biotech Holding AG's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-83.591/0.029
=-288,244.83 %

Veraxa Biotech Holding AG's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-37.64/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Veraxa Biotech Holding AG (VRXA) has a Net Margin % of 0.00% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Veraxa Biotech Holding AG and its competitors. According to the industry distribution chart, Veraxa Biotech Holding AG ranks #932 out of 943 companies in the Biotechnology industry, placing it in the top 98.8%.
Is Veraxa Biotech Holding AG's Net Margin % too high?
Veraxa Biotech Holding AG's current Net Margin % is 0.00%. Based on the distribution chart, Veraxa Biotech Holding AG ranks #932 out of 943 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Veraxa Biotech Holding AG has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Veraxa Biotech Holding AG's Net Margin % compare to TTRX and IRD?
According to the Biotechnology industry distribution chart, Veraxa Biotech Holding AG ranks #932 out of 943 companies for Net Margin %. This places Veraxa Biotech Holding AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Veraxa Biotech Holding AG and its competitors. Veraxa Biotech Holding AG's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veraxa Biotech Holding AG stock overvalued right now?
Veraxa Biotech Holding AG (VRXA) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Veraxa Biotech Holding AG's overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Veraxa Biotech Holding AG (VRXA), the current Net Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Veraxa Biotech Holding AG Business Description

Other Exchanges J8L0:Germany
Address Talacker 35, Zurich, CHE, 8001
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
6GF Score

Get the complete analysis for VRXA

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.77
Price